TESARO Inc (TSRO)

NASDAQ
74.96
0.00(0.00%)
  • Volume:
    0
  • Day's Range:
    74.94 - 74.97
  • 52 wk Range:
    0.00 - 0.00

TSRO Overview

Prev. Close
74.94
Day's Range
74.94-74.97
Revenue
219.37M
Open
74.95
52 wk Range
0-0
EPS
-11.91
Volume
0
Market Cap
4.14B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,005,148
P/E Ratio
-
Beta
0.38
1-Year Change
0%
Shares Outstanding
55,231,566
Next Earnings Date
-
What is your sentiment on TESARO?
or
Vote to see community's results!

TESARO Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

TESARO Inc Analysis

TESARO Inc Company Profile

TESARO Inc Company Profile

Employees
715

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. As of January 22, 2019, Tesaro, Inc. operates as a subsidiary of GlaxoSmithKline plc.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyBuy
SummaryBuyStrong BuyStrong BuyStrong BuyStrong Buy
  • Reuters predicts a gain of 66.3% from today's price. Total range was $35 to $100.
    0
    • TSRO is take-out target as we speak. Buy it before it is too late! $220-$230 per share..
      1
      • Getting murdered on this one. When is reversal?
        0
    • anyone here??
      0
      • Yep. Looks like a good time to buy TSRO. The stock has taken a beating lately, but it really isn't justified.
        0